User profiles for Mark N. Polizzotto
 | Mark PolizzottoClinical Hub for Interventional Research (CHOIR), The Australian National University Verified email at anu.edu.au Cited by 4693 |
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a …
…, S Osei, D Margolis, Q Zhu, MN Polizzotto… - The Lancet Infectious …, 2022 - thelancet.com
Background We aimed to assess the efficacy and safety of two neutralising monoclonal
antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-…
antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-…
[HTML][HTML] Castleman disease
Castleman disease (CD), a heterogeneous group of disorders that share morphological
features, is divided into unicentric CD and multicentric CD (MCD) according to the clinical …
features, is divided into unicentric CD and multicentric CD (MCD) according to the clinical …
[HTML][HTML] Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine …
MN Polizzotto, TS Uldrick, D Hu… - Frontiers in microbiology, 2012 - frontiersin.org
Soon after the discovery of Kaposi sarcoma (KS)-associated herpesvirus (KSHV), it was
appreciated that this virus was associated with most cases of multicentric Castleman disease (…
appreciated that this virus was associated with most cases of multicentric Castleman disease (…
HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults
People with human immunodeficiency virus (HIV) have higher rates of certain comorbidities,
particularly cardiovascular disease and cancer, than people without HIV 1 , 2 , 3 , 4 – 5 . In …
particularly cardiovascular disease and cancer, than people without HIV 1 , 2 , 3 , 4 – 5 . In …
Kaposi sarcoma–associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment
Kaposi sarcoma associated herpesvirus (KSHV), a γ2-herpesvirus, also known as human
herpesvirus-8, is the etiologic agent of three virally associated tumors: Kaposi sarcoma, a …
herpesvirus-8, is the etiologic agent of three virally associated tumors: Kaposi sarcoma, a …
Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated inflammation: prospective characterization of KSHV …
MN Polizzotto, TS Uldrick, KM Wyvill… - Clinical Infectious …, 2016 - academic.oup.com
Background. Kaposi sarcoma herpesvirus (KSHV) is the cause of Kaposi sarcoma (KS),
primary effusion lymphoma (PEL), and a form of Castleman disease (KSHV-MCD). Recently a …
primary effusion lymphoma (PEL), and a form of Castleman disease (KSHV-MCD). Recently a …
Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease
MN Polizzotto, TS Uldrick, V Wang… - Blood, The Journal …, 2013 - ashpublications.org
Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a
polyclonal B-cell lymphoproliferative disorder. Human (h) IL-6 and a KSHV-encoded …
polyclonal B-cell lymphoproliferative disorder. Human (h) IL-6 and a KSHV-encoded …
High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy
TS Uldrick, MN Polizzotto, K Aleman… - Blood, The Journal …, 2011 - ashpublications.org
Kaposi sarcoma herpesvirus (KSHV)–associated multicentric Castleman disease (MCD) is
a lymphoproliferative disorder most commonly observed in HIV-infected patients. It is …
a lymphoproliferative disorder most commonly observed in HIV-infected patients. It is …
[HTML][HTML] Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled …
…, F Gordin, MK Jain, V Kan, MN Polizzotto… - The Lancet …, 2019 - thelancet.com
Background Since the 1918 influenza pandemic, non-randomised studies and small clinical
trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous …
trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous …
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
MN Polizzotto, J Nordwall, AG Babiker, A Phillips… - The Lancet, 2022 - thelancet.com
Background Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG)
to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific …
to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific …